Metabolic response as assessed by 18 F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or high-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

Douglas J Harrison, Yueh-Yun Chi, Jing Tian, Pooja Hingorani, Leo Mascarenhas, Geoffrey B McCowage, Brenda J Weigel, Rajkumar Venkatramani, Suzanne L Wolden, Torunn I Yock, David A Rodeberg, Andrea A Hayes-Jordan, Lisa A Teot, Sheri L Spunt, William H Meyer, Douglas S Hawkins, Barry L Shulkin, Marguerite T Parisi

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

BACKGROUND: Strategies to optimize management in rhabdomyosarcoma (RMS) include risk stratification to assign therapy aiming to minimize treatment morbidity yet improve outcomes. This analysis evaluated the relationship between complete metabolic response (CMR) as assessed by 18 F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET) imaging and event-free survival (EFS) in intermediate-risk (IR) and high-risk (HR) RMS patients.

METHODS: FDG-PET imaging characteristics, including assessment of CMR and maximum standard uptake values (SUVmax) of the primary tumor, were evaluated by central review. Institutional reports of SUVmax were used when SUVmax values could not be determined by central review. One hundred and thirty IR and 105 HR patients had FDG-PET scans submitted for central review or had SUVmax data available from institutional report at any time point. A Cox proportional hazards regression model was used to evaluate the relationship between these parameters and EFS.

RESULTS: SUVmax at study entry did not correlate with EFS for IR (p = 0.32) or HR (p = 0.86) patients. Compared to patients who did not achieve a CMR, EFS was not superior for IR patients who achieved a CMR at weeks 4 (p = 0.66) or 15 (p = 0.46), nor for HR patients who achieved CMR at week 6 (p = 0.75) or 19 (p = 0.28). Change in SUVmax at week 4 (p = 0.21) or 15 (p = 0.91) for IR patients or at week 6 (p = 0.75) or 19 (p = 0.61) for HR patients did not correlate with EFS.

CONCLUSION: Based on these data, FDG-PET does not appear to predict EFS in IR or HR-RMS. It remains to be determined whether FDG-PET has a role in predicting survival outcomes in other RMS subpopulations.

Original languageEnglish (US)
Pages (from-to)857-866
Number of pages10
JournalCancer medicine
Volume10
Issue number3
DOIs
StatePublished - Dec 19 2020

Bibliographical note

Funding Information:
Children's Oncology Group Grants U10CA180886, U10CA180899, U10CA098543, and U10CA098413; Imaging and Radiation Oncology Core Group (IROC) U10CA180803, and Quality Assurance Review Center (QARC) U10CA29511; St. Baldrick's Foundation. James R Anderson, PhD.

Publisher Copyright:
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Keywords

  • chemotherapy
  • complete metabolic response
  • maximum standard uptake value (SUVmax)
  • pediatric
  • positron emission tomography
  • rhabdomyosarcoma

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

Fingerprint

Dive into the research topics of 'Metabolic response as assessed by 18 F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or high-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee'. Together they form a unique fingerprint.

Cite this